title: [Effect of retinoic acid on the cytogenetic remission in the first chronic phase of chronic myeloid leukemia treated with interferon].
abstract: Cytogenetic responses of 11 chronic myeloid leukemic (CML) patients during the first chronic phase, treated with the combination of all-trans retinoic acid (ATRA) + interferon (IFN) were compared to 9 other CML patients of phase one, treated with interferon monotherapy. Metaphase and interphase cytogenetics and a semiquantitative polymerase chain reaction (PCR) were used to evaluate the cytogenetic responses. Two of the 11 patients in the ATRA + interferon treated group were withdrawn, one of them because of interferon intolerance, and the other because of compliance failure. Among the 9 ATRA + interferon treated patients 6 major cytogenetic responses could be detected and 3 of them were complete. Of the 9 patients treated with IFN monotherapy only 2 major cytogenetic responses could be registered. No severe adverse effects were observed. The first results suggest that the ATRA + interferon combination may be superior in achieving cytogenetic remission in the first chronic phase of CML.
authors.affiliation: Belgyógyászati Osztály, Kaposi Mór Megyei Kórház, Kaposvár. egyedmiklos@yahoo.com
authors.forename: M
authors.initials: M
authors.lastname: Egyed
authors.forename: Z
authors.initials: Z
authors.lastname: Mihályfalvi
authors.forename: B
authors.initials: B
authors.lastname: Kollár
authors.forename: G
authors.initials: G
authors.lastname: Rumi
authors.forename: E
authors.initials: E
authors.lastname: Keller
authors.forename: J
authors.initials: J
authors.lastname: Vass
authors.forename: S
authors.initials: S
authors.lastname: Fekete
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D005260:Female; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D007399:Interphase / Q000187:drug effects; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012074:Remission Induction; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use*
chemical_list: D014212:Tretinoin; D007372:Interferons
vernacular_title: Retinsav hatása a citogenetikai remisszióra krónikus myeloid leukaemia interferonnal kezelt elsó krónikus fázisában.